Dr. Darrin Vincent Bann, MD, PhD

Dr. Bann practices at SouthPark Surgery Center in Charlotte, North Carolina.

Dr. Bann's NPI, 1437544152, was assigned on March 31, 2015. Dr. Bann graduated from Penn State College of Medicine in 2015. Dr. Bann's North Carolina license number on file is 2022-00575.

Dr. Bann's primary practice is SouthPark Surgery Center, at 6035 Fairview Road, Charlotte, NC 28210. The practice phone is (704) 295-3080.

Dr. Bann's primary practice is SouthPark Surgery Center in Charlotte, North Carolina. The medical group on file is Charlotte Eye Ear Nose & Throat Associates (CEENTA). Dmand AI also links Dr. Bann to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bann practices, 2 sites in all. Vendor and product names are available with a free account.

Pediatric otolaryngology is Dr. Bann's primary specialty in the NPI Registry, under taxonomy code 207YP0228X. Dr. Bann is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Bann's licenses on file in 2 states: North Carolina and Pennsylvania.

Dmand AI lists acute sinusitis, ear eustachian tube disorders, ear infection, endoscopic sinus surgery, swimmer's ear, tinnitus, upper respiratory infection (URI) and vertigo among the conditions Dr. Bann treats.

CMS data shows 35 Medicare services from Dr. Bann across 2 procedure codes in 2023, all of them office visits, for 31 Medicare patients. Medicare paid $1,652 for them. Every service was in an office.

CMS counts 31 Medicare patients who saw Dr. Bann in 2024. The largest group is 65 to 74, with 15 patients. 65% of them have high blood pressure, and 61% have high cholesterol. Their average risk score is 1.17, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Bann's median patient age at 5, with 44% women.

In 2020, Dr. Bann wrote 15 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $87 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Bann for performance year 2024, reported through an alternative payment model (APM). Dr. Bann accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 39 papers to Dr. Bann, published from 2012 to 2021. 2012 was the busiest year, with 5. The most frequent topics are Thyroid Neoplasms, Adenoma and Coronavirus Infections. Dr. Bann has published most often in Ear Nose Throat J. Dr. Bann's most frequent co-authors are Neerav Goyal, MD, Leslie J. Parent, MD and Vijay A. Patel, MD.

CMS Open Payments shows 8 general payments to Dr. Bann from 7 drug and device companies from 2022 to 2024. Food and beverage make up the largest share, 100% of the total. Integra LifeSciences Corporation paid the most, $165.

Dmand AI lists 3 awards for Dr. Bann, most recently Dean’s Award for Scholarly Achievement in 2015. Dr. Bann serves on Centralized Otolaryngology Research Effort Study Section, Head and Neck Surgery Subcommittee.

Dr. Bann graduated from Penn State College of Medicine in 2015. Dr. Bann is a member of NHS, ATA, Pennsylvania Academy of Otolaryngology and Sigma Xi: The Scientific Research Society.

Dr. Bann is in network with 18 carriers, including Aetna, Blue Cross Blue Shield of Michigan and HCSC. HMO plans come from the most carriers, 11. Check the plan with the practice before a visit.